bpc-157 side effects human studies Frontiers What is BPC-157? | Everything

The efficacy of the injectable GLP-1 RAs semaglutide and liraglutide in inducing WL and weight maintenance through appetite reduction has led to clinical trials assessing higher doses of these molecules as treatments for obesity and both semaglutide 2.4 mg once weekly and liraglutide 3 mg once daily have now received approval for chronic weight management [17,18]

J Vasc Surg

Unlike the proven and regulated forms of regenerative medicine that have undergone extensive testing, BPC-157 has not met the benchmarks for safety and efficacy required for medical use in humans

In the obesity trial, serious adverse events (SAEs) occurred in 4% of participants with retatrutide use overall (06% across groups) vs